A Pharmaceutical Company Disrupt the Treatment Paradigm to Treat Various Eye Diseases
In this segment, Neal speaks with healthcare veteran Nancy Lurker, President and CEO of EyePoint Pharmaceuticals, who discussed how Lurker transformed EyePoint in five years with a robust pipeline of developing and commercializing innovative therapies to help improve the lives of patients with serious eye disorders and plans to double its staff again in 2022.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
As President and Chief Executive Officer and Board Director, Nancy Lurker leads EyePoint Pharmaceuticals in its mission to improve the lives of people facing serious eye disorders. During her more than 30 years in the pharmaceutical industry, Ms. Lurker has driven scientific and commercial innovation working with both public and private companies from start-ups to the Fortune 500 to bring innovative therapies and diagnostic solutions to patients.
Prior to joining EyePoint in 2016, Ms. Lurker was President and CEO and Board Director of PDI, Inc., a NASDAQ-listed healthcare commercialization company which was sold to Publicis Health. Before joining PDI, she was Senior Vice President and Chief Marketing Officer at Novartis Pharmaceuticals. She also served as President and CEO of ImpactRx, Inc., a privately held healthcare information company. Prior to ImpactRx, Ms. Lurker was Group VP, Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career as a Senior Medical Representative at Bristol Myers Squibb, where she quickly rose to Senior Director of Worldwide Cardiovascular Franchise Management, overseeing numerous successful drug launches.
Ms. Lurker currently serves on the Board of Directors of Eyepoint Pharmaceuticals, Altasciences, and Aquestive Therapeutics, and as a member of the Novo Holdings Advisory Board. She has previously held positions on the Boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, Conjuchem, and ImpactRx.
Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. Dedicating her career to maximizing the potential of science to improve the lives of patients, Ms. Lurker is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
